Clovis Oncology Inc (CLVS)

71.96
NASDAQ : Health Care
Prev Close 69.87
Day Low/High 68.50 / 74.73
52 Wk Low/High 16.61 / 99.45
Avg Volume 1.95M
Exchange NASDAQ
Shares Outstanding 48.88M
Market Cap 3.42B
EPS -9.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why

Several stocks spent Monday's trading session in the red, and here's why.

Clovis Oncology To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 2

Clovis Oncology To Announce Second Quarter 2017 Financial Results And Host Webcast Conference Call On August 2

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2017 financial results on Wednesday, August 2, 2017, after the close of the U.

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares.

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.

Biotech Movers: AveXis, Clovis, Epizyme

Biotech Movers: AveXis, Clovis, Epizyme

AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20.

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million.

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.

Clovis Oncology's Rucaparib Significantly Improved Progression-Free Survival In All Ovarian Cancer Patient Populations Studied In Phase 3 ARIEL3 Maintenance Treatment Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by...

Biotech Movers: Acceleron, Clovis, Coherus

Biotech Movers: Acceleron, Clovis, Coherus

Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday.

Clovis Oncology Announces Presentations At 2017 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual...

Analysts' Actions -- AMD, Clovis, ConocoPhillips, Disney, Transocean and More

Analysts' Actions -- AMD, Clovis, ConocoPhillips, Disney, Transocean and More

Here are Wednesday's top research calls, including new coverage of Advanced Micro Devices and Transocean, upgrades for Clovis Oncology and ConocoPhillips, and a downgrade for Disney.

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update

Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.

Clovis Oncology Announces First Quarter 2017 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2017, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder of...

Clovis Oncology To Announce First Quarter 2017 Financial Results And Host Webcast Conference Call On May 3

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced

Tesaro's newly approved PARP inhibitor Zejula is really 50% more expensive than its list price implies.

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.

These Stocks Show a Change of Direction

These Stocks Show a Change of Direction

Finding bullish and bearish reversals in the market.

Clovis Oncology Announces Data Presentations At AACR Annual Meeting 2017

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that rucaparib preclinical data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2017.

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

Look for Clovis Oncology to Resume Its Advance

Look for Clovis Oncology to Resume Its Advance

More gains await patient CLVS holders.

Notable Wednesday Option Activity: CLVS, KMG, NYLD

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Clovis Oncology Inc , where a total volume of 7,551 contracts has been traded thus far today, a contract volume which is representative of approximately 755,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.5% of CLVS's average daily trading volume over the past month, of 1.8 million shares.

Goldman Sachs Raises Clovis Oncology Price Target to $75

Goldman Sachs Raises Clovis Oncology Price Target to $75

Clovis Oncology closed trading below $67 on Tuesday.

6 Stocks Trending Up With Major Volume

6 Stocks Trending Up With Major Volume

Here's a technical look at how to play a number of stocks trending higher with strong volume.

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results

AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.

Clovis Oncology Presents New Data From Phase 2 Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women's Cancer

Clovis Oncology, Inc. (NASDAQ:CLVS) announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in...

Clovis Oncology Announces 2016 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for 2017.